Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pentostatin + cyclophosphamide + busulfan + antithymocyte globulin rabbit
- Development stage
- Unknown
- Lead developer
- National Cancer Institute
- Modality
- Small Molecules, Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
ATL-RIC is a reduced-intensity conditioning (RIC) regimen developed by the National Cancer Institute (NCI) for use prior to allogeneic hematopoietic cell transplantation (HCT). Originally designed for patients with Adult T-cell Leukemia/Lymphoma (ATL), it has also been evaluated in clinical trials for other Peripheral T-cell Lymphomas (PTCL). The regimen is a multi-drug combination consisting of the adenosine deaminase inhibitor pentostatin, the alkylating agents cyclophosphamide and busulfan, and rabbit anti-thymocyte globulin (rATG). This combination is intended to provide potent immunosuppression and cytoreduction to facilitate donor stem cell engraftment and induce a graft-versus-lymphoma effect while minimizing the treatment-related mortality associated with standard myeloablative conditioning, particularly in older or heavily pretreated patients.
- Other names
- ATL-RIC regimenAdult T-cell Leukemia Reduced Intensity Conditioning
02
Targets
ADA (Adenosine deaminase)DNA
Beyond the preview
Go deeper on pentostatin + cyclophosphamide + busulfan + antithymocyte globulin rabbit.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pentostatin + cyclophosphamide + busulfan + antithymocyte globulin rabbit.